Sling has secured $123 million in funding to accelerate the development of its oral thyroid eye disease drug, positioning itself as a potential competitor to Amgen’s Tepezza, the current market leader. This significant investment underscores the growing interest in innovative treatments for thyroid eye disease, a condition that affects many patients and has seen limited therapeutic options until now.
The funding will enable Sling to expedite clinical trials and regulatory submissions, potentially bringing its oral IGF-1R blocker to market ahead of competitors. As the first oral treatment in this category, it could reshape the treatment landscape, offering patients a more convenient alternative to existing therapies, which often require injections. The implications for market dynamics are substantial, as successful entry into this niche could not only enhance patient adherence but also challenge established players like Amgen, prompting a shift in pricing and treatment strategies across the sector.
Use the database as your supply chain compass →
